期刊文献+

局部注射锑剂治愈皮肤利什曼病一例 被引量:2

A case of cutaneous leishmaniasis successfully treated with local injection of antimony preparations
下载PDF
导出
摘要 患者男,25岁。因右肩部丘疹、斑块7个月,渗出伴结痂3个月就诊。发病前曾于尼日利亚工作,有蚊虫叮咬史。按皮肤利什曼病给予局部清创并口服甲硝唑、氟康唑治疗2个月无效。皮损组织病理示:表皮萎缩,真皮浅中层弥漫性组织细胞浸润,部分细胞内外见利杜小体,伴浆细胞及嗜酸粒细胞浸润;过碘酸-雪夫染色(PAS)阳性;聚合酶链反应(PCR)分子测序显示为硕大利什曼原虫(Leishmania major),明确皮肤利什曼病诊断。患者采用伊曲康唑联合特比萘芬口服、外用盐酸特比萘芬治疗1个月无效,随后使用葡萄糖酸锑钠治疗,3个月后皮损痊愈。 The patient was a 25-year-old male who presented with papules and plaques on right shoulder for 7 months, with exudation and crusts for 3 months. The patient had once worked in Nigeria and suffered from mosquito bites. He was considered as "cutaneous leishmaniasis" and treated with metronidazole and fluconazole which didn't produce any therapeutic effects. The skin biopsy showed epidermal atrophy, many histocytes diffused in dermis with a lot of Leishman-Donovani bodys in and around them, the result of PAS was positive, and the result of PCR confirmed the pathogen was Leishmania major. After the failure of oral itraconazole and terbinafine for 1 month, glucantime therapy was given, 3 months later, the patient's lesions healed with hypertrophic scar.
出处 《实用皮肤病学杂志》 2017年第3期186-188,共3页 Journal of Practical Dermatology
关键词 皮肤利什曼病 抗真菌药物 锑剂 Cutaneous leishmaniasis Antifungal drugs Glucantime
  • 相关文献

参考文献3

二级参考文献16

  • 1Nisha Singh,Manish Kumar,Rakesh Kumar Singh.Leishmaniasis:Current status of available drugs and new potential drug targets[J].Asian Pacific Journal of Tropical Medicine,2012,5(6):485-497. 被引量:5
  • 2李志军,刘流,何黎.外用咪喹莫特的研究进展[J].国际皮肤性病学杂志,2006,32(3):144-146. 被引量:17
  • 3Allen CM Jr. Isoprene-containing metabolites of Aspergillus amstelodami. Can J Microbiol, 1972, 18(8): 1275-1282.
  • 4Sampaio RN, Takano GI~ Malacame AC, et al. In vivo terbinafine inefficacy on cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis in C57BL/6 mice. Rev Soc Bras Med Trop, 2003, 36(4): 531-533.
  • 5Vannier-Santos MA, Urbina JA, Martiny A, et al. Alterations induced by the antifungal compounds ketoconazole and terbinafine in Leishmania. J Eukaryot Microbiol, 1995, 42(4): 337-346.
  • 6Balfour JA, Faulds D. Terbinafin~ A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs, 1992, 43(2): 259-284.
  • 7Rangel H, Dagger F, Hemandez A, et al. Naturally azole-resistant Leishmania brzziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole- susceptible Leishmania mexicana promastigotes. Antimicrob Agents Chemother, 1996, 40 (12): 2785-2791.
  • 8Gonzdlez-Rup6rez J, Javaloyas de Morlius M, Moreno Carazo A. Remis- sion: of localized cutaneous leishmaniasis in a HIV-positive patient using systemic terbiuafine. Dermatology, 1997, 194 ( 1 ): 85-86.
  • 9Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther, 2010, 8(4): 419-433.
  • 10Geiser DM, Klich MA, Frisvad JC, et al. The current status of species recognition and identification in Aspergillus. Stud Mycol, 2007, 59: 1-10.

共引文献8

同被引文献25

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部